Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Price:
30.83 USD
1.85%
Market Closed
Updated:
May 6, 2024
Supernus Pharmaceuticals Inc
Cash from Operating Activities
|
Supernus Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
Cash from Operating Activities
$111.1m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$23.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$3.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
See Also
What is Supernus Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
111.1m
USD
111.1m
USD
Based on the financial report for Dec 31, 2023, Supernus Pharmaceuticals Inc's Cash from Operating Activities amounts to 111.1m USD.
What is Supernus Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-3%
-3%
Over the last year, the Cash from Operating Activities growth was -5%. The average annual Cash from Operating Activities growth rates for Supernus Pharmaceuticals Inc have been -7% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
